Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5122 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD5122 oral suspension (part A and B) |
| 2 | PLACEBO_COMPARATOR | Placebo oral suspension (part A) |
| 3 | EXPERIMENTAL | AZD5122 oral and IV infusion (part B) |
| Name | Type | Description |
|---|---|---|
| AZD5122 | DRUG | A single dose of oral suspension |
| Placebo | DRUG | A single dose of oral suspension |
Inclusion Criteria: * Provision of signed and dated, written informed consent. * Normal physical examination, laboratory values, blood pressure and pulse * Healthy male caucasian subjects Exclusion Criteria: * Subjects must not have any history of gastrointestinal, hepatic or renal disease, or an...
AZD5122 is an investigational small molecule being developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial involving healthy male volunteers. The specific therapeutic indication for AZD5122 has not been disclosed.
AZD5122 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is a global biopharmaceutical company headquartered in the United Kingdom.
AZD5122 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
AZD5122 has been evaluated in a single Phase 1 trial, NCT00984477, titled "Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects." The trial was completed and enrolled 100 healthy male participants in the United Kingdom.
The therapeutic use of AZD5122 has not been disclosed. It has been tested only in healthy volunteers in a Phase 1 trial, so no specific disease indication has been publicly identified for this investigational small molecule.